Literature DB >> 10537348

Relative expression of matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 in mouse renal cell carcinoma cells regulates their metastatic potential.

H Miyake1, I Hara, K Gohji, K Yamanaka, S Hara, S Arakawa, M Nakajima, S Kamidono.   

Abstract

To clarify the significance of the balance between matrix metalloproteinase-2 (MMP-2) and tissue inhibitor of metalloproteinase-2 (TIMP-2) in the progression of renal cell carcinoma, we transfected both the MMP-2 and TIMP-2 genes simultaneously into RenCa, a mouse renal cell carcinoma cell line that does not express detectable levels of either MMP-2 or TIMP-2 mRNAs, and established several clones with various MMP-2:TIMP-2 expression ratios. On the basis of the quantitative evaluation of the MMP-2: TIMP-2 mRNA expression ratio by Northern blot analysis, we selected a clone overexpressing MMP-2 alone (RenCa/M), a clone overexpressing TIMP-2 alone (RenCa/T), and two kinds of clones overexpressing both, i.e., one with a high (RenCa/MTh) and one with a low (RenCa/MTl) MMP-2: TIMP-2 ratio, to compare the tumor cell phenotypes. In an in vitro tumor cell invasion assay, the MMP-2:TIMP-2 ratios of the RenCa sublines were directly correlated with their invasive potential. The invasive abilities of the parental RenCa cells induced by conditioned media from RenCa sublines were also correlated with the MMP-2:TIMP-2 ratios of the sublines. The cell adhesion assay showed the inverse correlation between the MMP-2 expression levels in the sublines and their cell adhesion to several extracellular matrix components. Furthermore, when injected i.v. or into the renal subcapsule in syngeneic mice, RenCa sublines formed metastatic nodules in the lungs, and the number of nodules was correlated with the MMP-2:TIMP-2 ratio of each clone. In contrast, despite the growth-inhibitory effects of TIMP-2 overexpression, MMP-2 overexpression had no effect on either proliferation in vitro of RenCa sublines or on their growth as tumors in vivo. These results suggest that the MMP-2:TIMP-2 expression ratio is a critical factor in the invasion and metastasis of renal cell carcinoma.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10537348

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  6 in total

Review 1.  A case of tumor betrayal: biphasic effects of TIMP-1 on Burkitt's lymphoma.

Authors:  L Yan; M A Moses
Journal:  Am J Pathol       Date:  2001-04       Impact factor: 4.307

2.  Matricellular proteins as modulators of cell-matrix interactions: adhesive defect in thrombospondin 2-null fibroblasts is a consequence of increased levels of matrix metalloproteinase-2.

Authors:  Z Yang; T R Kyriakides; P Bornstein
Journal:  Mol Biol Cell       Date:  2000-10       Impact factor: 4.138

3.  Macrophage-dependent nitric oxide expression regulates tumor cell detachment and metastasis after IL-2/anti-CD40 immunotherapy.

Authors:  Jonathan M Weiss; Lisa A Ridnour; Tim Back; S Perwez Hussain; Peijun He; Anna E Maciag; Larry K Keefer; William J Murphy; Curtis C Harris; David A Wink; Robert H Wiltrout
Journal:  J Exp Med       Date:  2010-10-04       Impact factor: 14.307

4.  Gene Expression of Matrix Metalloproteinases and their Inhibitors (TIMPs) in Meningiomas of Dogs.

Authors:  M T Mandara; A Reginato; G Foiani; S De Luca; G Guelfi
Journal:  J Vet Intern Med       Date:  2017-09-05       Impact factor: 3.333

5.  Enhanced progression of human prostate cancer PC3 cells induced by the microenvironment of the seminal vesicle.

Authors:  M Kumano; H Miyake; T Kurahashi; K Yamanaka; M Fujisawa
Journal:  Br J Cancer       Date:  2008-01-08       Impact factor: 7.640

6.  Computational Modelling of Metastasis Development in Renal Cell Carcinoma.

Authors:  Etienne Baratchart; Sébastien Benzekry; Andreas Bikfalvi; Thierry Colin; Lindsay S Cooley; Raphäel Pineau; Emeline J Ribot; Olivier Saut; Wilfried Souleyreau
Journal:  PLoS Comput Biol       Date:  2015-11-23       Impact factor: 4.475

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.